BeOne MedicinesMEX:BGNEN 81 Interest Coverage is 7.60 as of Mar. 2026, which is 1% below its 10-year median of 7.68. GuruFocus rates MEX:BGNEN with a GF Score™ of 81/100 and a GF Value™ of MXN3,774.03. The stock has 4 warning signs investors should review. Among 377 Biotechnology companies, BeOne Medicines ranks worse than 80.9% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. BeOne Medicines's
Operating Income
for the
three
months ended in Mar. 2026 was MXN4,506 Mil. BeOne Medicines's Interest Expense for the
three
months ended in Mar. 2026 was MXN-593 Mil.
BeOne Medicines's interest coverage for the quarter that ended in Mar. 2026 was 7.60.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for BeOne Medicines's Interest Coverage or its related term are showing as below:
MEX:BGNEN'
s Interest Coverage Range Over the Past 10 Years
Min: 7.53 Med: 7.68 Max: 7.68
Current: 7.53
MEX:BGNEN's Interest Coverage is ranked worse than 80.9% of 377
companies
in the Biotechnology industry
Industry Median: 106.07
vs MEX:BGNEN: 7.53
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
BeOne Medicines Interest Coverage Related Terms
BeOne Medicines Interest Coverage Historical Data
* Premium members only.
The historical data trend for BeOne Medicines's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MEX:BGNEN vs RVMD, RPRX, BNTX: Interest Coverage Comparison
For the Biotechnology subindustry, BeOne Medicines's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Interest Coverage distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeOne Medicines (MEX:BGNEN) has a Interest Coverage of 7.60 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BeOne Medicines and its competitors. This is near median its historical median of 7.68. Over the past decade, BeOne Medicines' Interest Coverage has ranged from 7.53 to 7.68. According to the industry distribution chart, BeOne Medicines ranks #305 out of 377 companies in the Biotechnology industry, placing it in the top 80.9%.
Is BeOne Medicines' Interest Coverage too high?
BeOne Medicines' current Interest Coverage of 7.60 is near median its 10-year median of 7.68. Over the past 10 years, this metric has ranged from a low of 7.53 to a high of 7.68. The Biotechnology industry median Interest Coverage is 106.07. BeOne Medicines' value of 7.60 is 92.8% below this industry median. Based on the distribution chart, BeOne Medicines ranks #305 out of 377 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeOne Medicines has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Interest Coverage compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #305 out of 377 companies for Interest Coverage. This places BeOne Medicines in the lower half of its industry. The industry median Interest Coverage is 106.07. BeOne Medicines' value of 7.60 is 92.8% below this benchmark. Historically, BeOne Medicines' own Interest Coverage has ranged from 7.53 to 7.68 over the past decade. While the company's 10-year median is 7.68 vs. the industry median of 106.07, BeOne Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 106.07, based on 377 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Interest Coverage of 7.60 is 92.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BeOne Medicines and its competitors. For the Biotechnology industry, the median Interest Coverage is 106.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Interest Coverage is 7.60, which is near median its own 10-year median of 7.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
BeOne Medicines (MEX:BGNEN) has a current Interest Coverage of 7.60. The stock's GF Value™ is MXN3,774.03, compared to a current price of MXN2,858.16 — trading 24.3% below its estimated fair value. The current Interest Coverage is 7.60, which is near median its 10-year median of 7.68 and 92.8% below the Biotechnology industry median of 106.07. BeOne Medicines' overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BeOne Medicines (MEX:BGNEN), the current Interest Coverage is 7.60 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (MEX:BGNEN) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of MXN2,858.16 is trading 24.3% below its estimated GF Value™ of MXN3,774.03.
Key valuation signals for MEX:BGNEN:
Interest Coverage: 7.60 (near median its 10-year median of 7.68)
GF Value™: MXN3,774.03 vs. price of MXN2,858.16 (24.3% below fair value)
Industry Position: 92.8% below the Biotechnology median (#305 of 377)
No single metric tells the full story. See the MEX:BGNEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
81GF Score
Get the complete analysis for MEX:BGNEN
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BGNEN has been successfully added to your 
